KOL
September 13, 2021

LARVOL VIEW Top 100 Most Influential Oncologists on Twitter 2021

KOL
June 8, 2021

LARVOL VIEW Top 100 Most Influential Oncologists on Twitter 2021

Author

LARVOL VIEW Top 100 is a curated list of the most influential Digital Opinion Leaders (DOLs) in oncology on Twitter. Our methodology selects and ranks DOLs based on online influence, offline activity, and the opinions of other verified oncologists.

Top oncologists are turning to Twitter for important conversations with their peers. In fact, there are almost 500 tweets every week posted by verified oncologists related to trending news in cancer research, trials, treatments, and drug development. This trend is growing, and a group of over 1,200 Digital Opinion Leaders (DOLs) has emerged as an important voice in the community.  

Today, we recognize the leading voices among DOLs with the 2021 LARVOL VIEW Top 100 Most Influential Oncologists on Twitter. This curated list represents the 100 oncologists with the largest influence on the cancer conversation on Twitter, balanced with analysis of their offline activity in the field and the input of their peers.  

Download the 2021 List

The 100 oncologists on our list stand out as those who are leading the way online and taking advantage of the full potential of Twitter as a tool to educate and inspire their peers, and the medical community.

How was this list developed?

To identify voices of influence on Twitter, the LARVOL team started by tracking oncology news on Twitter, then built out a list of oncologists who were actively sharing and reacting to that news. We then implemented a weighted methodology to select and rank DOLs based on online influence, offline activity, and the opinions of other verified oncologists. Each score is weighted equally to produce the final LARVOL VIEW Top 100 ranking.

1. Online Rank: Measured by Twitter Followers and Reactions to oncology news (posts comments and quote tweets, as captured by VIEW)

2. Offline Rank: Measured by participation in ongoing Clinical Trials and Citations from the last 5 years (Google Scholar)

3. Peer Survey Rank: Nominations from peers in LARVOL VIEW Top 100 survey

The oncologists recognized on this year’s list were celebrated at LARVOL’s “Night at the Museum,” a unique event held in virtual reality on the final night of ASCO’s 2021 Virtual Meeting.  

The LARVOL VIEW Top 100 Most Influential Oncologists on Twitter is powered by VIEW, the first social listening and sentiment analysis platform focused on Twitter-verified oncologists, researchers, and DOLs. VIEW also presents a feed of curated oncology news from Twitter alongside the reactions of verified oncologists.  

Contact us for more information on VIEW and download your list of the top 100 influential voices in oncology.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.